Summary:The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was у3 × 10 6 CD34 + cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34 Despite the high curability rate of aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) with front-line therapy, only a small fraction of patients with refractory or relapsing disease can be successfully managed using standard-dose salvage chemotherapy. The encouraging results of high-dose therapy (HDT) with peripheral blood stem cell (PBSC) support have been widely demonstrated in both diseases.1,2 Over the last few years, PBSCs have come to be preferred over autologous bone marrow because of their ability to shorten the myelosuppressed period, accelerate engraftment of both neutrophils and platelets, and reduce blood product and antibiotic requirements. 3,4 Hematopoietic growth factors with or without high-dose cyclophosphamide are considered standard procedures for adequate mobilization of PBSCs, 5 although other combinations of chemotherapy and growth factors have also been used. A number of studies have demonstrated the superiority of the combination of chemotherapy and growth factors over either element alone, as well as the correlation between the intensity of the chemotherapy with the number of mobilized PBSCs.6-11 The best option is therefore a regimen that embodies both proven mobilizing and adequate antineoplastic activity.The efficacy of ifosfamide and/or vinorelbine-based chemotherapy as salvage regimens for poor prognosis lymphoma has also been demonstrated. [12][13][14][15][16][17][18] Gemcitabine has recently been shown to be active in heavily pretreated HD patients, with a response rate of 40% and a low level of drug-related toxicity.